The apparent benefits at 2 years observed in the nonrandomized ALT-FLOW study pave the way for a sham-controlled trial.

Endovascular Engineering, Inc. (E2) announced it has secured $42 million in oversubscribed Series B financing to advance its n ...

Effective dyspnea evaluation in urgent care requires the usage of a systems-based framework for categorizing the differential ...

St. Vincent’s Riverside is now offering a breakthrough treatment for patients diagnosed with chronic pulmonary obstructive ...